Renaissance Technologies LLC grew its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 31.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,098,840 shares of the company's stock after purchasing an additional 500,120 shares during the period. Renaissance Technologies LLC owned approximately 1.41% of Xeris Biopharma worth $7,115,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in XERS. Legato Capital Management LLC purchased a new stake in shares of Xeris Biopharma during the 4th quarter valued at $482,000. Barclays PLC grew its stake in shares of Xeris Biopharma by 87.8% in the third quarter. Barclays PLC now owns 324,472 shares of the company's stock worth $925,000 after purchasing an additional 151,685 shares during the last quarter. Geode Capital Management LLC raised its position in Xeris Biopharma by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company's stock valued at $9,502,000 after purchasing an additional 93,091 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Xeris Biopharma by 106.2% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company's stock worth $581,000 after buying an additional 88,224 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Xeris Biopharma by 30.3% in the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company's stock worth $292,000 after acquiring an additional 23,843 shares during the period. Institutional investors own 42.75% of the company's stock.
Insider Transactions at Xeris Biopharma
In other news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.56% of the company's stock.
Xeris Biopharma Price Performance
Shares of NASDAQ XERS traded up $0.20 during mid-day trading on Thursday, hitting $4.33. 694,159 shares of the company's stock traded hands, compared to its average volume of 1,864,313. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.69 and a 1 year high of $6.07. The company's 50-day moving average is $4.47 and its two-hundred day moving average is $3.72. The company has a market capitalization of $665.79 million, a P/E ratio of -9.59 and a beta of 1.37.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum increased their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research note on Friday, March 7th. Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners upped their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $6.10.
Read Our Latest Stock Analysis on XERS
Xeris Biopharma Profile
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Articles
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
